Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation

被引:349
|
作者
Kurki, S
Peltonen, K
Latonen, L
Kiviharju, TM
Ojala, PM
Meek, D
Laiho, M
机构
[1] Univ Helsinki, Biomedicum, Haartman Inst, FIN-00014 Helsinki, Finland
[2] Univ Helsinki, Biomedicum, Mol Canc Biol Res Program, FIN-00014 Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Diagnost Lab, FIN-00014 Helsinki, Finland
[4] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland
基金
芬兰科学院;
关键词
D O I
10.1016/S1535-6108(04)00110-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nucleophosmin (NPM, B23) is an abundant nucleolar phosphoprotein involved in ribosome biogenesis, and interacts with tumor suppressor proteins p53 and Rb. Here we show that NPM is a UV damage response protein that undergoes nucleoplasmic redistribution and regulates p53 and HDM2 levels and their interaction. By utilizing RNAi approaches and analyses of endogenous and ectopically expressed proteins, we demonstrate that NPM binds HDM2 and acts as a negative regulator of p53-HDM2 interaction. Viral stress, enforced by expression of Kaposi's sarcoma virus K cyclin, causes NPM redistribution, K cyclin-NPM association, and p53 stabilization by dissociation of HDM2-p53 complexes. The results demonstrate novel associations of HDM2 and K cyclin with NPM and implicate NPM as a crucial controller of p53 through inhibition of HDM2.
引用
收藏
页码:465 / 475
页数:11
相关论文
共 50 条
  • [21] Inhibitors of the Hdm2:p53 complex as antitumour agents
    Westwell, AD
    DRUG DISCOVERY TODAY, 2006, 11 (7-8) : 371 - 371
  • [22] Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?
    Fischer, PM
    Lane, DP
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (07) : 343 - 346
  • [23] HUMAN p53 AND Hdm2: CLONING AND CONSTRUCTION OF EXPRESSION PLASMID
    Nguyen, Khue Vu
    ANALYTICAL LETTERS, 2010, 43 (02) : 323 - 334
  • [24] The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53
    Higashitsuji, H
    Higashitsuji, H
    Itoh, K
    Sakurai, T
    Nagao, T
    Sumitomo, H
    Masuda, T
    Dawson, S
    Shimada, Y
    Mayer, RJ
    Fujita, J
    CANCER CELL, 2005, 8 (01) : 75 - 87
  • [25] Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2
    Oh, Wonkyung
    Lee, Eun-Woo
    Sung, Young Hoon
    Yang, Mi-Ran
    Ghim, Jaewang
    Lee, Han-Woong
    Song, Jaewhan
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (25) : 17457 - 17465
  • [26] Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2
    Sengupta, S
    Wasylyk, B
    GENES & DEVELOPMENT, 2001, 15 (18) : 2367 - 2380
  • [27] Hdm2 disrupts HdmX-mediated nuclear export of p53 by sequestering it in nucleus
    Ni, Yue
    Chen, Hongce
    Cheng, Xuecheng
    Sun, Beini
    Wu, Zhirui
    Zhan, Qiuqiang
    Zhuang, Zhengfei
    EXPERIMENTAL CELL RESEARCH, 2024, 441 (02)
  • [28] AURKA-mediated Activation of HDM2 Regulates p53 in Upper Gastrointestinal Cancers
    Sehdev, Vikas
    Katsha, Ahmed M.
    Peng, DunFa
    Belkhiri, Abbes
    Soutto, Mohammed
    Ecsedy, Jeffrey
    Zaika, Alexander
    El-Rifai, Wael
    GASTROENTEROLOGY, 2013, 144 (05) : S167 - S167
  • [29] Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2
    Kitagaki, Jirouta
    Agama, Keli K.
    Pommier, Yves
    Yang, Yili
    Weissman, Allan M.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (08) : 2445 - 2454
  • [30] Robust Generation of Lead Compounds for Protein-Protein Interactions by Computational and MCR Chemistry: p53/Hdm2 Antagonists
    Czarna, Anna
    Beck, Barbara
    Srivastava, Stuti
    Popowicz, Grzegorz M.
    Wolf, Siglinde
    Huang, Yijun
    Bista, Michal
    Holak, Tad A.
    Doemling, Alexander
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2010, 49 (31) : 5352 - 5356